Shares of NxStage Medical (NASDAQ:NXTM) have earned an average broker rating score of 2.00 (Buy) from the six brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong sell recommendation, one has given a hold recommendation and four have given a strong buy recommendation to the company.

Brokers have set a 1-year consensus price target of $21.00 for the company and are expecting that the company will post ($0.10) EPS for the current quarter, according to Zacks. Zacks has also assigned NxStage Medical an industry rank of 152 out of 265 based on the ratings given to related companies.

Shares of NxStage Medical (NASDAQ:NXTM) opened at 14.25 on Wednesday. NxStage Medical has a 52 week low of $11.50 and a 52 week high of $19.63. The stock has a 50-day moving average of $15.74 and a 200-day moving average of $17.31. The company’s market cap is $901.14 million.

NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings data on Wednesday, May 6th. The medical device company reported ($0.09) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.11) by $0.02. The company had revenue of $79.50 million for the quarter, compared to the consensus estimate of $77.92 million. During the same quarter last year, the company posted ($0.09) earnings per share. NxStage Medical’s revenue was up 10.1% compared to the same quarter last year. On average, analysts predict that NxStage Medical will post $-0.36 earnings per share for the current fiscal year.

Separately, analysts at Zacks reiterated a “hold” rating on shares of NxStage Medical in a research note on Thursday, June 4th.

In other NxStage Medical news, President Joseph E. Turk, Jr. sold 2,000 shares of the stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $15.36, for a total transaction of $30,720.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jeffrey H. Burbank sold 20,000 shares of NxStage Medical stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $15.56, for a total transaction of $311,200.00. The disclosure for this sale can be found here.

NxStage Medical, Inc. (NASDAQ:NXTM)is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). The Company operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it sells and rents the System One, PureFlow SL equipment and disposable products in the home and critical care markets. In the In-Center segment, it sells of blood tubing sets and needles for hemodialysis at dialysis centers and needles for apheresis. The Company’s products include the NxStage System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.

To get a free copy of the research report on NxStage Medical (NXTM), click here. For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.

...